No science in the numbers but my point is you need to reward good sales people. Just indicating good sales people are costly. I dont know any business that have said a sales guy in the US costs less than $200K.
Printable View
No science in the numbers but my point is you need to reward good sales people. Just indicating good sales people are costly. I dont know any business that have said a sales guy in the US costs less than $200K.
Before I get jumped on and asked for links to factually prove that there are 20 (or so) people in the US it is just a number I vaguely recall from a post on this thread.
Nothing else ... I may have been completely wrong but it ties with indicative US spend PEB provided
I'd have thought that these guys were out there educating the market for now, not selling kits as suggested here!
Why do you expect PEB to make real sales at this point if Medicare, Vets and Private Insurers are not covering?
Cxbladder needs approval first, old boy networking is not going to change this. Urologist endorsement and clinical utility will be the real test.
I don't dismiss or misunderstand the power of the big Players at all, but am under no illusions as to the job at hand and patience needed.
Seems like the PEB thread has been hollowed out of late.
I would put money on it that many holders have done little to no research especially the ones selling out sub 80c.
I have enjoyed lurking this site for several years now but with some posters claiming that research has gone to PM I don't want to miss out.
In an effort to try and revitalise this thread and bring back some of the posters I will put out some discussion material.
Quick re-cap
We have a class leading test that in clinical testing has proven to be superior in detection rates to current practice alone.
http://www.cxbladder.com/assets/Mark...l-Study-US.pdf
It is more comfortable and cheaper than cytoscopy(edit) but is not a replacement for cytoscopy(edit) it will work in conjunction with it.
There is competition from existing tests although they are inferior, they are promoted by big pharma.
Discuss
We have a market for our product and a gap - see the link provided from a study in the US that less than 10% of patients presented with hematuria are referred for bladder screening.
Of those reporting hematuria a little over 1/3 were in the high risk category and met the study criteria (over 40, no previous hematuria work up, 18 months previous data) and of the this 2455 of 6585 only 1/ were treated with some sort of work up. The reasons for this are touched on but significant to us "Practice site was also a significant predictor of referral. Several sites had markedly lower rates of diagnostic testing for patients with hematuria (P < .001 for all sites)."Variability based on nonclinical factors, such as practice site, is undesirable and may be amenable to quality-improvement initiatives, process improvement for coordination of care, and a reduction in logistical barriers for providers and patients," Dr. Friedlander said.
http://www.medscape.com/viewarticle/813239#1
Wouldnt things be a lot easier if you could just piss in a cup...? Then post it away? _ Pacific edge have stated that they are exceeding the expected turnaround of tests done so far.
I will pre-empt a potential argument "there are existing competing tests why arent they using them?" Because from my research the existing tests do not have the accuracy and if they have the accuracy it will be at the cost of an unacceptable amount of false positives.
And to answer a question above "Distribution channels are not as important as the effectiveness of the diagnostic test - surely?" Well we need both, plenty of examples of a superior product failing against big money.
Our current concerns as shareholders are the wait for CMS coverage, the growth curve (the exponential effect could have us doing 1000 tests, 5000, 20,000 60,000 100,000)
The potential need for another capital raising although the company thinks it will be OK I am skeptical of that claim but would love to see that level of sales it would provide a huge boost to the share price.
Looking forward
The release of the companies other products will be able to slingshot in if CX bladder is a success as pathways and relationships will be in place and if not they they atleast add to the takeover likelyhood and price.
The concerns over DD ability must be looked at knowing that we also have a US CEO.
The medical community is a hard nut to crack and although there is shady monetary deals - doctors and urologists are people of science and have empathy and are very logical.
I believe the patient(pun intended) will be rewarded here with either a buyout or a minimum 5 bagger not including other products if it goes for gold.
I have my own uptake curve which is is more conservative that pacific edge's but still values the company higher than current share price.
Woops cytology instead of cytoscopy, have corrected. Will come back to cytoscopy later will require some digging up old info.
As for the discuss section - lots of hematuria not investigated although the article didnt have all the reasons why we know that the current gold standard is not an easy test and hence patients are graded on risk rather than widespread testing. As for practice site being significant I read that as - a number of sites doing less testing due to various issues with administering the test whether the access to urological facilities, number of practitioners etc. The CX bladder tests are portable and would require very little training and largely avoid logistical issues.
As for the US CEO, Jackie Walker, She led a biotech startup previously and is in in charge of US growth. DD has been criticized for not being capable of leading US growth but he is not soley responsible for that.
Most recently Jackie was President and CEO of OSspray, a UK headquartered biotech start-up. She led the company from founding IP technology through business plan development and fund raising to clinical validation, regulatory approval, global product commercialisation, and scale-up leading to strategic acquisition.
David Darling, CEO of Pacific Edge, said: ‘we are thrilled to have Jackie Walker drive our growth in the US. She is a strategic, results-oriented, and passionate executive with 25 years experience in the Life Sciences/Medical Device Industry. She has an outstanding background in P&L management, Sales and Marketing, New Product Development, and Operations. Her experience spans large global companies as well as start-ups.’
Psychic, this from the PEB website about cytoscopy and cx bladder
How Cxbladder can be used in your practice:
- Replace the need for other urine-based tests in primary workup.
- Complement cystoscopy for bladder cancer detection.
- Detect urothelial tumours not visible by cystoscopy.
- Replace the need for CT / IVP in primary workup in some instances.
- Improve patient compliance with accurate, non-invasive testing.
Other applications may include:
- Complement cystoscopy for monitoring bladder cancer recurrence.
- Increase the interval between surveillance cystoscopies in certain circumstances.
- Triage patients presenting with micro-haematuria that do not need a full workup.
- Patient prioritisation in high throughput settings.
- Evaluate patients in ‘at-risk’ populations.
The resident lab rat isn't happy today. As some of you recall the unfortunate rat presented just over 3 weeks ago with a UTI and some bleeding and a very bad fever that landed him in the hospital. Luckily said rat was aware of the CX bladder test and felt fortunate to live in the Waitemata DHB area where he knows they've had a pilot programme running for a while so after the antibiotics cleared up his UTI he very reluctantly headed down to his doctor when he finally ran out of Vitamen D and blood pressure pills to face the music on what follow up tests the poor old rodent would have to confront
The good news was that some bleeding with UTI's is not uncommon and there was a clear case of infection detected in the rat's blood so the rat perked up a bit when he heard that and asked what the hospital had recommended be done in terms of follow up tests in the letter they said they'd write to the Doctor. What letter ? Somewhat concerned the rat become somewhat agitated and thought he'd cut too the chase if he wanted his lunch anytime that day..,have you heard about the Cx bladder test programme being run by the Waitemata DHB ?, (doctor is highly experienced and lives in Waitemata DHB area), what CX bladder test ?
Hmmm, rat becomes uncomfortable and explains to his own doctor what's involved and ponders how a doctor living in the Waitemata DHB isn't aware of the test or the pilot programme and wonders if he's not aware of it, how would others be ?
Luckily Rat remembers to bring his printed out blood analysis along, (which he asked for when in hospital) and gives that to his Doctor.
If he hadn't asked for that and brought it along there would be nothing too go on at this stage, which goes to show a smart rat looks after his own health).
Doctor spots something in the blood analysis he doesn't like so orders another blood sample, (Rat is too scared too ask what), and a three phase urine sample with some microscope analysis looking for cancer cells, (rats eye's are starting too glaze over as he's now lost in medical jargon, so he blurted out, perhaps seeing as they were going to write too you with follow up action and seeing as you havn't got that letter, you should write to them and ask for a recommended follow up course of action including whether we should do a CX bladder test. Doctor agrees this is a good course of action but cautions about how long it might take for their reply.
Rat slinks off to ponder whether he's really received decent health care service from professionals and wonders if his doctor hasn't even heard of it how many others wouldn't have either.